Loading Quotes...


Spring 2019 Group Meeting registration is open More Here

Applications are now being accepted from CRAs and data managers for limited travel assistance to the Spring 2019 Group Meeting (deadline March 29) More Here

ECOG-ACRIN is now issuing a monthly e-Newsletter More Here


The Journal of Clinical Oncology says “Landmark advances in molecular diagnostics continue, with the most significant achievement in 2018 made as a result of the TAILORx breast cancer study” More Here


TAILORx is among the notable articles of 2018 in The New England Journal of Medicine — one of two cancer advances on the list of 12 More Here


ABC News features Joseph Sparano, MD, and the TAILORx trial in ‘Surprising Discoveries’ Watch Program


Oncology Times features 2018 Young Investigator Symposium presenters Read Article


First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients, E1912 Trial Shows Clinical Oncology 


E2511 trial finds that adding veliparib to frontline chemotherapy is effective for patients with extensive-stage small-cell lung cancer Journal of Clinical Oncology


E1912 trial results in practice change for CLL patients Read Press Release


Genome Web: ‘Black Women with Breast Cancer Fare Worse’ according to TAILORx data Read Article (requires free registration)





Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair







img img